Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Adult Acute Myelomonocytic Leukemia

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Adult Acute Myelomonocytic Leukemia cohort.

Asset / SponsorPhaseRating
Azacitidine
University of Chicago
Phase 2BB
METHOTREXATE
National Cancer Institute (NCI)
Phase 3BB
Fluconazole
Children's Oncology Group
Phase 3BB
CASPOFUNGIN
Children's Oncology Group
Phase 3BB
Hycamtin
National Cancer Institute (NCI)
Phase 2BB

View all 11 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →